BACKGROUND & AIMS: Prior studies suggest the rate of liver fibrosis progression is slower in African Americans (AAs) than Caucasian Americans (CAs) with chronic HCV infection. METHODS: With a multi-state Markov model, fibrosis progression was evaluated in a well-characterized cohort of 143 AA and 157 CA adults with untreated chronic HCV genotype 1 infection. In subjects with a history of injection drug use, duration of infection was imputed from a fitted risk model rather than assumed to be the reported first year of use. RESULTS: The distribution of Ishak fibrosis stages was 0 (8.7%), 1/2 (55.7%), 3/4 (29.3%), and 5/6 (6.3%) and was similar in AAs and CAs (P = .22). After adjusting for biopsy adequacy, AAs had a 10% lower rate of fibrosis progression than did CAs, but the difference was not statistically significant (hazard ratio, 0.90; 95% confidence interval, 0.72-1.12). The overall 20-year estimates of probabilities of progression from stage 0 to stages 1/2, 3/4, and 5/6 were 59.3%, 28.8%, and 4.7%, respectively. The estimated median time from no fibrosis to cirrhosis was 79 years for the entire cohort and 74 and 83 years for CAs and AAs, respectively. In 3-variable models including race and biopsy adequacy, the factors significantly associated with fibrosis progression were age when infected, steatosis, ALT level, and necroinflammatory score. CONCLUSIONS: The rates of fibrosis progression were slow and did not appear to differ substantially between AAs and CAs.
BACKGROUND & AIMS: Prior studies suggest the rate of liver fibrosis progression is slower in African Americans (AAs) than Caucasian Americans (CAs) with chronic HCV infection. METHODS: With a multi-state Markov model, fibrosis progression was evaluated in a well-characterized cohort of 143 AA and 157 CA adults with untreated chronic HCV genotype 1 infection. In subjects with a history of injection drug use, duration of infection was imputed from a fitted risk model rather than assumed to be the reported first year of use. RESULTS: The distribution of Ishak fibrosis stages was 0 (8.7%), 1/2 (55.7%), 3/4 (29.3%), and 5/6 (6.3%) and was similar in AAs and CAs (P = .22). After adjusting for biopsy adequacy, AAs had a 10% lower rate of fibrosis progression than did CAs, but the difference was not statistically significant (hazard ratio, 0.90; 95% confidence interval, 0.72-1.12). The overall 20-year estimates of probabilities of progression from stage 0 to stages 1/2, 3/4, and 5/6 were 59.3%, 28.8%, and 4.7%, respectively. The estimated median time from no fibrosis to cirrhosis was 79 years for the entire cohort and 74 and 83 years for CAs and AAs, respectively. In 3-variable models including race and biopsy adequacy, the factors significantly associated with fibrosis progression were age when infected, steatosis, ALT level, and necroinflammatory score. CONCLUSIONS: The rates of fibrosis progression were slow and did not appear to differ substantially between AAs and CAs.
Authors: L B Seeff; R N Miller; C S Rabkin; Z Buskell-Bales; K D Straley-Eason; B L Smoak; L D Johnson; S R Lee; E L Kaplan Journal: Ann Intern Med Date: 2000-01-18 Impact factor: 25.391
Authors: D L Thomas; J Astemborski; R M Rai; F A Anania; M Schaeffer; N Galai; K Nolt; K E Nelson; S A Strathdee; L Johnson; O Laeyendecker; J Boitnott; L E Wilson; D Vlahov Journal: JAMA Date: 2000-07-26 Impact factor: 56.272
Authors: A J Freeman; G J Dore; M G Law; M Thorpe; J Von Overbeck; A R Lloyd; G Marinos; J M Kaldor Journal: Hepatology Date: 2001-10 Impact factor: 17.425
Authors: Varun Saxena; Jennifer C Lai; Jacqueline G O'Leary; Elizabeth C Verna; Robert S Brown; R Todd Stravitz; James F Trotter; Kartik Krishnan; Norah A Terrault Journal: Liver Transpl Date: 2012-05 Impact factor: 5.799
Authors: Mei Lu; Jia Li; Loralee B Rupp; Yueren Zhou; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Joseph A Boscarino; Yihe G Daida; Mark A Schmidt; Sheri Trudeau; Stuart C Gordon Journal: Liver Int Date: 2017-07-21 Impact factor: 5.828
Authors: Jennifer C Lai; Jacqueline G O'Leary; James F Trotter; Elizabeth C Verna; Robert S Brown; R Todd Stravitz; Jeffrey D Duman; Lisa M Forman; Norah A Terrault Journal: Liver Transpl Date: 2012-05 Impact factor: 5.799
Authors: Dana Lau-Corona; Luís Alberto Pineda; Héctor Hugo Avilés; Gabriela Gutiérrez-Reyes; Blanca Eugenia Farfan-Labonne; Rafael Núñez-Nateras; Alan Bonder; Rosalinda Martínez-García; Clara Corona-Lau; Marco Antonio Olivera-Martínez; Maria-Concepción Gutiérrez-Ruiz; Guillermo Robles-Díaz; David Kershenobich Journal: World J Gastroenterol Date: 2009-06-07 Impact factor: 5.742
Authors: Manhal Izzy; Ghalib Jibara; Aws Aljanabi; Mustafa Alani; Emily Giannattasio; Hina Zaidi; Zaid Said; Paul Gaglio; Allan Wolkoff; John F Reinus Journal: J Clin Exp Hepatol Date: 2016-03-12
Authors: Jennifer C Price; Yifei Ma; Rebecca Scherzer; Natalie Korn; Kyle Tillinghast; Marion G Peters; Susan M Noworolski; Phyllis C Tien Journal: Hepatology Date: 2017-02-03 Impact factor: 17.425
Authors: Monika Sarkar; Peter Bacchetti; Audrey L French; Phyllis Tien; Marshall J Glesby; Marek Nowicki; Michael Plankey; Stephen Gange; Gerald Sharp; Howard Minkoff; Marion G Peters Journal: Hepatology Date: 2012-08-27 Impact factor: 17.425